WO2008143880A2 - Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales - Google Patents

Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales Download PDF

Info

Publication number
WO2008143880A2
WO2008143880A2 PCT/US2008/006158 US2008006158W WO2008143880A2 WO 2008143880 A2 WO2008143880 A2 WO 2008143880A2 US 2008006158 W US2008006158 W US 2008006158W WO 2008143880 A2 WO2008143880 A2 WO 2008143880A2
Authority
WO
WIPO (PCT)
Prior art keywords
pkc
bryostatin
head trauma
brain injury
traumatic brain
Prior art date
Application number
PCT/US2008/006158
Other languages
English (en)
Other versions
WO2008143880A3 (fr
WO2008143880A8 (fr
Inventor
Ofer Zohar
Daniel L. Alkon
Original Assignee
Blanchette Rockefeller Neurosciences Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/068,742 external-priority patent/US9974832B2/en
Application filed by Blanchette Rockefeller Neurosciences Institute filed Critical Blanchette Rockefeller Neurosciences Institute
Publication of WO2008143880A2 publication Critical patent/WO2008143880A2/fr
Publication of WO2008143880A3 publication Critical patent/WO2008143880A3/fr
Publication of WO2008143880A8 publication Critical patent/WO2008143880A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the treatment of head trauma with compounds that activate protein kinase C (PKC) or boost nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors.
  • PLC protein kinase C
  • NGF boost nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • Traumatic head injury is a trauma to the head, that may or may not include injury to the brain (see also brain injury).
  • the incidence (number of new cases) of traumatic head injury is 300 per 100,000 per year (0.3% of the population), with a mortality of 25 per 100,000 in North America and 9 per 100,000 in Germany.
  • Head trauma also referred to as head injury or traumatic head injury, herein
  • head injury is a common cause of childhood hospitalization.
  • Traumatic head injuries include both injuries to the brain and those to other parts of the head, such as the scalp and skull. Head injuries may be closed or open. A closed (non- missile) head injury is one in which the skull is not broken. A penetrating head injury occurs when an object pierces the skull and breaches the dura mater. Brain injuries may be diffuse, occurring over a wide area, or focal, located in a small, specific area. A head injury may cause a skull fracture, which may or may not be associated with injury to the brain. Some patients may have linear or depressed skull fractures. If intracranial hemorrhage, or bleeding within the brain occurs, a hematoma within the skull can put pressure on the brain.
  • Types of intracranial hematoma include subdural, subarachnoid, extradural, and intraparenchymal hematoma. Craniotomy surgeries are used in these cases to lessen the pressure by draining off blood. Head trauma is caused by a concussive event.
  • Brain injury can be at the site of impact, but can also be at the opposite side of the skull due to a corcoup effect (the impact to the head can cause the brain to move within the skull, causing the brain to impact the interior of the skull opposite the head-impact). If the impact causes the head to move, the injury may be worsened, because the brain may ricochet inside the skull (causing additional impacts), or the brain may stay relatively still (due to inertia) but be hit by the moving skull.
  • Brain injuries range from severe to minimal. Victims of severe to moderate traumatic brain injury are easily diagnosed. However, majority of traumatic brain injury victims suffer from mild to minimal traumatic brain injury and many of them are released from medical care undiagnosed. Still, most of these patients suffer long-term cognitive, emotional and sleep disorders.
  • PKC has been identified as one of the largest gene families of non-receptor serine-threonine protein kinases. Since the discovery of PKC in the early eighties by Nishizuka and coworkers (Kikkawa et al. (1982) J. Biol. Chem. 257: 13341), and its identification as a major receptor for phorbol esters (Ashendel et al. (1983) Cancer Res., 43: 4333), a multitude of physiological signaling mechanisms have been ascribed to this enzyme. The intense interest in PKC stems from its unique ability to be activated in vitro by calcium and diacylglycerol (and its phorbol ester mimetics), an effector whose formation is coupled to phospholipid turnover by the action of growth and differentiation factors.
  • PKC protein kinase C
  • NGF nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4- methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.
  • PKC protein kinase C
  • MCBA 4- methylcatechol acetic acid
  • the PKC activator is FGF-18, a macrocyclic lactone, a benzolactam, a pyrrolidinone, or a combination thereof.
  • the macrocyclic lactone is a bryostatin or neristatin.
  • the neristatin is neristatin-1.
  • the bryostatin is bryostatin- 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17 or 18. More preferably, the bryostatin is bryostatin-1.
  • the pharmaceutical composition comprises 4- methylcatechol acetic acid (MCBA), other derivatives of methylcatechol, or a brain derived neurotrophic factor.
  • MCBA and other derivatives of methylcatechol activate or upregulate nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) or other neurotrophic factors.
  • NGF nerve growth factor
  • BDNF brain derived neurotrophic factor
  • NGF activates, upregulates or enhances the activity of PKC which in turn upregulates, activates or enhances NGF.
  • administration of the pharmaceutical compositions of the present invention is initiated within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days of said head trauma. In another embodiment, said administration is initiated between 1 and 2 days, 1 and 3 days, 1 and 4 days, 1 and 5 or 1 and 7 days of said head trauma. In another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated within 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours of said head trauma. In yet another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated between 1 and 3, 1 and 5, 1 and 10, 1 and 24, 3 and 5, 3 and 10, 3 and 24, 5 and 10, 5 and 24, or 10 and 24 hours after said head trauma.
  • the administration of the pharmaceutical compositions of the present invention is initiated after 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours after said head trauma. In yet another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days after said head trauma.
  • treatment comprising the administration of the pharmaceutical compositions of the present invention is continued for a duration of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, or 12 weeks.
  • Figure 1 depicts the escape latencies of mice after minimal traumatic brain injury
  • Figure 2 depicts the escape latencies of mice after minimal traumatic brain injury
  • TBI (TBI) (30g):followed by 30ug/kg bryostatin injected intraperitoneal Iy.
  • Figure 3 depicts memory retention in mice after minimal TBI (30g) followed by
  • administration includes any route of administration, including oral subcutaneous, intraperitoneal, and intramuscular.
  • an effective amount is an amount sufficient to reduce one or more symptoms associated with a head trauma.
  • protein kinase C activator or “PKC activator” means a substance that increases the rate of the reaction catalyzed by protein kinase C by binding to the protein kinase C.
  • the term "subject" means a mammal.
  • the term "pharmaceutically acceptable carrier” means a chemical composition with which the active ingredient may be combined and which, following the combination, can be used to administer the active ingredient to a subject.
  • physiologically acceptable ester or salt means an ester or salt form of the active ingredient which is compatible with any other ingredients of the pharmaceutical composition, which is not deleterious to the subject to which the composition is to be administered.
  • pharmaceutically acceptable carrier also includes, but is not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; sweetening agents; flavoring agents; coloring agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials.
  • compositions of the invention are known in the art and described, for example in Genaro, ed., 1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., which is incorporated herein by reference.
  • compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
  • preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.
  • compositions are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates, and other mammals.
  • the area of memory and learning impairment is rich in animal models that are able to demonstrate different features of memory and learning processes. (See, for example, Hollister, L. E., 1990, Pharmacopsychiat, 23, (Suppl II) 33-36).
  • the available animal models of memory loss and impaired learning involve measuring the ability of animals to remember a discrete event. These tests include the Morris Water Maze and the passive avoidance procedure. In the Morris Water Maze, animals are allowed to swim in a tank divided into four quadrants, only one of which has a safety platform beneath the water. The platform is removed and the animals are tested for how long they search the correct quadrant verse the incorrect quadrants.
  • PLC Protein Kinase C
  • the PKC gene family consists presently of 1 1 genes which are divided into four subgroups: 1) classical PKC ⁇ , ⁇ i, ⁇ 2 ( ⁇ i and ⁇ 2 are alternatively spliced forms of the same gene) and ⁇ , 2) novel PKC ⁇ , ⁇ , ⁇ , and ⁇ , 3) atypical PKC ⁇ , ⁇ , ⁇ and / and 4) PKC ⁇ .
  • PKC ⁇ resembles the novel PKC isoforms but differs by having a putative transmembrane domain (reviewed by Blohe et al. (1994) Cancer Metast. Rev. 13: 41 1 ; Hug et al. (1993) Biochem J.
  • the ⁇ , ⁇ ,, ⁇ 2 and ⁇ isoforms are C 2+ , phospholipid and diacylglycerol-dependent and represent the classical isoforms of PKC, whereas the other isoforms are activated by phospholipid and diacylglycerol but are not dependent on Ca 2+ . All isoforms encompass 5 variable (V1-V5) regions, and the ⁇ , ⁇ and ⁇ isoforms contain four (C1-C4) structural domains which are highly conserved.
  • isoforms except PKC ⁇ , ⁇ and ⁇ lack the C2 domain
  • the ⁇ ⁇ and isoforms also lack nine of two cysteine-rich zinc finger domains in Cl to which diacylglycerol binds.
  • the Cl domain also contains the pseudosubstrate sequence which is highly conserved among all isoforms, and which serves an autoregulartory function by blocking the substrate-binding site to produce an inactive conformation of the enzyme (House et al. (1987) Science 238, 1726).
  • PKC isozymes play different, sometimes opposing, roles in biological processes, providing two directions for pharmacological exploitation.
  • One is the design of specific (preferably, isozyme specific) inhibitors of PKC. This approach is complicated by the act that the catalytic domain is not the domain primarily responsible for the isotype specificity of PKC.
  • the other approach is to develop isozyme- selective, regulatory site-directed PKC activators. These may provide a way to override the effect of other signal transduction pathways with opposite biological effects. Alternatively, by inducing down-regulation of PKC after acute activation, PKC activators may cause long term antagonism. Bryostatin is currently in clinical trials as an anti-cancer agent.
  • the bryostatins are known to bind to the regulatory domain of PKC and to activate the enzyme.
  • Bryostatins are examples of isozyme-selective activators of PKC. (see for example WO 97/43268; incorporated herein by reference in its entirety).
  • PKC modulators see PCT/US97/08141, U.S. Patent Nos. 5,652,232; 6,043,270; 6,080,784; 5,891,906; 5,962,498; 5,955,501 ; 5,891 ,870 and 5,962,504 (each of which is incorporated herein by reference in its entirety).
  • PKC activators [0031] Several classes of PKC activators have been identified. Phorbol esters, however, are not suitable compounds for eventual drug development because of their tumor promotion activity, (Ibarreta et al. (1999) Neuro Report 10(5&6): 1035-40). Of particular interest are macrocyclic lactones (i.e. bryostatin class and neristatin class) that act to stimulate PKC. Of the bryostatin class compounds., bryostatin- 1 has been shown to activate PKC and proven to be devoid of tumor promotion activity. Bryostatin- 1, as a PKC activator, is also particularly useful since the dose response curve of bryostatin- 1 is biphasic.
  • bryostatin- 1 demonstrates differential regulation of PKC isozymes, including PKC ⁇ , PKC ⁇ and PKC ⁇ .
  • Bryostatin-1 has undergone toxicity and safety studies in animals and humans and is actively investigated as an anti-cancer agent. Bryostatin-1 's use in the studies has determined that the main adverse reaction in humans is myalgia.
  • One example of an effective dose is 20 or 30 ⁇ g/kg per dose by intraperitoneal injection.
  • PKC activators Several classes have been identified. Phorbol esters, however, are not suitable compounds for eventual drug development because of their tumor promotion activity, (Ibarreta et al. (1999) Neuro Report 10(5&6): 1035-40). Of particular interest are macrocyclic lactones (i.e. bryostatin class and neristatin class) that act to stimulate PKC. Of the bryostatin class compounds, bryostatin-1 has been shown to activate PKC and proven to be devoid of tumor promotion activity. Bryostatin-1, as a PKC activator, is also particularly useful since the dose response curve of bryostatin-1 is biphasic.
  • bryostatin-1 demonstrates differential regulation of PKC isozymes, including PKC ⁇ , PKC ⁇ and PKC ⁇ .
  • Bryostatin-1 has undergone toxicity and safety studies in animals and humans and is actively investigated as an anti-cancer agent.
  • Bryostatin- l 's use in the studies has determined that the main adverse reaction in humans is myalgia.
  • One example of an effective dose is 20 or 30 ⁇ g/kg per dose by intraperitoneal injection.
  • macrocyclic lactone compounds and their derivatives are amenable to combinatorial synthetic techniques and thus libraries of the compounds can be generated to optimize pharmacological parameters, including, but not limited to efficacy and safety of the compositions. Additionally, these libraries can be assayed to determine those members that preferably modulate oc-secretase and/or PKC.
  • Combinatorial libraries high throughput screening of natural products and fermentation broths has resulted in the discovery of several new drugs.
  • generation and screening of chemical diversity is being utilized extensively as a major technique for the discovery of lead compounds, and this is certainly a major fundamental advance in the area of drug discovery.
  • combinatorial techniques provide for a valuable tool for the optimization of desired biological activity.
  • the subject reaction readily lend themselves to the creation of combinatorial libraries of compounds for the screening of pharmaceutical, or other biological or medically- related activity or material-related qualities.
  • a combinatorial library for the purposes of the present invention is a mixture of chemically related compounds, which may be screened together for a desired property; said libraries may be in solution or covalently linked to a solid support.
  • the preparation of many related compounds in a single reaction greatly reduces and simplifies the number of screening processes that need to be carried out. Screening for the appropriate biological property may be done by conventional methods.
  • the present invention also provides methods for determining the ability of one or more inventive compounds to bind to effectively modulate ⁇ -secretase and/or PKC.
  • bryostatin- 1 has two pyran rings and one 6-membered cyclic acetal
  • one of the pyrans of bryostatin- 1 is replaced with a second 6-membered acetal ring.
  • This modification reduces the stability of bryologs, relative to bryostatin- 1, for example, in both strong acid or base, but has little significance at physiological pH.
  • Bryologs also have a lower molecular weight (ranging from about 600 to 755), as compared to bryostatin- 1 (988), a property which facilitates transport across the blood-brain barrier.
  • B-ring bryologs are also suitable for use in the methods of the present invention.
  • a third class of suitable bryostatin analogs is the A-ring bryologs. These bryologs have slightly lower affinity for PKC than bryostatin I (6.5, 2.3, and 1.9 nM for bryologs 3, 4, and 5, respectively) but have a lower molecular weight.
  • DAG diacylglycerol
  • PKC activator expressly excludes DAG or DAG derivatives, such as phorbol esters.
  • Isoprenoids are PKC activators suitable for use in the methods of the present invention.
  • Farnesyl thiotriazole for example, is a synthetic isoprenoid that activates PKC with a Kd of 2.5 ⁇ M.
  • Farnesyl thiotriazole for example, is equipotent with dioleoylglycerol (Gilbert et al. (1995) Biochemistry 34: 3916; incorporated herein by reference in its entirety), but does not possess hydrolyzable esters of fatty acids.
  • Farnesyl thiotriazole and related compounds represent a stable, persistent PKC activator. Because of its low MW (305.5) and absence of charged groups, farnesyl thiotriazole would readily cross the blood-brain barrier.
  • Octylindolactam V is a non-phorbol protein kinase C activator related to teleocidin.
  • Napthalenesulfonamides including N-(n-heptyl)-5-chloro-l- naphthalenesulfonamide (SC-IO) and N-(6-Phenylhexyl)-5-chloro-l-naphthalenesulfonamide, are members of another class of PKC activators.
  • SC-IO activates PKC in a calcium-dependent manner, using a mechanism similar to that of phosphatidylserine (Ito et al. (1986) Biochemistry 25: 4179; incorporated herein by reference).
  • Naphthalenesulfonamides act by a different mechanism from bryostatin and would be expected to show a synergistic effect with bryostatin or a member of another class of PKC activators. Structurally, naphthalenesulfonamides are similar to the calmodulin (CaM) antagonist W-7, but are reported to have no effect on CaM kinase.
  • CaM calmodulin
  • DCP-LA (2-[(2-pentylcyclopropyl)methyl] cyclopropaneoctanoic acid
  • DCP-LA selectively activates PKC ⁇ with a maximal effect at 100 nM.
  • DCP-LA interacts with the phosphatidylserine binding site of PKC, instead of the diacylglycerol binding site.
  • Diacylglycerol kinase inhibitors such as 6-(2-(4- [(4-fluorophenyl)phenylmethylene]-l -piperidinyl)ethyl)-7-methyl-5H-thiazolo[3,2- a]pyrimidin-5-one (R59022) and [3-[2-[4-(bis-(4-fluorophenyl)methylene]piperidin- l - yl)ethyl]-2,3-dihydro-2-thioxo-4(l H)-quinazolinone (R59949) enhance the levels of the endogenous ligand diacylglycerol, thereby producing activation of PKC (Meinhardt et al. (2002) Anti-Cancer Drugs 13: 725).
  • Growth factor activators such as the 4-methyl catechol derivatives, such as 4- methylcatechol acetic acid (MCBA), that stimulate the synthesis and/or activation of growth factors such as NGF and BDNF, also activate PKC as well as convergent pathways responsible for synaptogenesis and/or neuritic branching.
  • 4-methyl catechol derivatives such as 4- methylcatechol acetic acid (MCBA)
  • MCBA 4- methylcatechol acetic acid
  • TBI minimal traumatic brain injury
  • TBI traumatic traumatic brain injury
  • TBI minimal traumatic brain injury

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte: sur l'utilisation de protéines kinases activant ou renforçant le facteur de croissance des nerf (NGF); sur le facteur tiré du cerveau (BDNF); sur d'autres facteurs neurotropes traitant les lésions traumatiques cérébrales (TBI), et spécifiquement, sur des méthodes de traitement des lésions traumatiques cérébrales comprenant les étapes suivantes: identification d'un sujet ayant subi une lésion traumatique cérébrale; administration au sujet d'une quantité efficace d'une préparation pharmaceutique comprenant un activateur de la protéine kinase C (PKC) ou de l'acide 4-méthylcatéchol acétique, dans un excipient ad hoc pour traiter au moins un symptôme de lésion traumatique cérébrale
PCT/US2008/006158 2007-05-24 2008-05-14 Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales WO2008143880A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92466207P 2007-05-24 2007-05-24
US60/924,662 2007-05-24
USPCT/US2008/001755 2008-02-11
US12/068,742 US9974832B2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
PCT/US2008/001755 WO2008100449A2 (fr) 2007-02-09 2008-02-11 Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales
US12/068,742 2008-02-11

Publications (3)

Publication Number Publication Date
WO2008143880A2 true WO2008143880A2 (fr) 2008-11-27
WO2008143880A3 WO2008143880A3 (fr) 2009-06-04
WO2008143880A8 WO2008143880A8 (fr) 2009-08-13

Family

ID=40091420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006158 WO2008143880A2 (fr) 2007-05-24 2008-05-14 Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales

Country Status (1)

Country Link
WO (1) WO2008143880A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006516A2 (fr) 2010-07-08 2012-01-12 Alkon Daniel L Activateurs de la protéine kinase c indirects et de type dag et anticoagulant pour le traitement de l'accident vasculaire cérébral
RU2470302C1 (ru) * 2011-09-21 2012-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования когнитивных нарушений в отдаленном периоде черепно-мозговой травмы
WO2014145316A1 (fr) 2013-03-15 2014-09-18 Alkon Daniel L Méthodes d'identification d'activateurs pkc neuroprotecteurs
WO2023133230A1 (fr) * 2022-01-08 2023-07-13 Sohn Joanna Monoacétyldiglycérides (plag) en tant qu'agent d'atténuation pour lésion cérébrale traumatique et lésion de reperfusion ischémique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004641A2 (fr) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Activation de la pkc utilisee pour renforcer la secretion de la sapp-a et pour ameliorer la gognition, au moyen de composes du type bryostatine
WO2004047857A1 (fr) * 2002-11-26 2004-06-10 Blanchette Rockefeller Neurosciences Institute Utilisation de fgf-18 dans le diagnostic et le traitement de troubles de la memoire
WO2006031337A2 (fr) * 2004-09-10 2006-03-23 Blanchette Rockefeller Neurosciences Institute Methode de traitement de la maladie d'alzheimer et d'amelioration cognitive
WO2008013573A1 (fr) * 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Procédés de stimulation de la croissance cellulaire, du remodelage synaptique et de la consolidation de la mémoire à long terme
WO2008100449A2 (fr) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004641A2 (fr) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Activation de la pkc utilisee pour renforcer la secretion de la sapp-a et pour ameliorer la gognition, au moyen de composes du type bryostatine
WO2004047857A1 (fr) * 2002-11-26 2004-06-10 Blanchette Rockefeller Neurosciences Institute Utilisation de fgf-18 dans le diagnostic et le traitement de troubles de la memoire
WO2006031337A2 (fr) * 2004-09-10 2006-03-23 Blanchette Rockefeller Neurosciences Institute Methode de traitement de la maladie d'alzheimer et d'amelioration cognitive
WO2008013573A1 (fr) * 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Procédés de stimulation de la croissance cellulaire, du remodelage synaptique et de la consolidation de la mémoire à long terme
WO2008100449A2 (fr) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006516A2 (fr) 2010-07-08 2012-01-12 Alkon Daniel L Activateurs de la protéine kinase c indirects et de type dag et anticoagulant pour le traitement de l'accident vasculaire cérébral
WO2012006510A1 (fr) 2010-07-08 2012-01-12 Alkon Daniel L Activateurs des protéine kinases c à base d'acides gras et anticoagulant pour le traitement de l'accident vasculaire cérébral
WO2012006525A2 (fr) 2010-07-08 2012-01-12 Alkon Daniel L Activateurs de pkc et anticoagulant dans un régime pour le traitement d'un accident vasculaire cérébral
RU2470302C1 (ru) * 2011-09-21 2012-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования когнитивных нарушений в отдаленном периоде черепно-мозговой травмы
WO2014145316A1 (fr) 2013-03-15 2014-09-18 Alkon Daniel L Méthodes d'identification d'activateurs pkc neuroprotecteurs
US20160025704A1 (en) * 2013-03-15 2016-01-28 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
WO2023133230A1 (fr) * 2022-01-08 2023-07-13 Sohn Joanna Monoacétyldiglycérides (plag) en tant qu'agent d'atténuation pour lésion cérébrale traumatique et lésion de reperfusion ischémique

Also Published As

Publication number Publication date
WO2008143880A3 (fr) 2009-06-04
WO2008143880A8 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
US20190083575A1 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
US10010584B2 (en) Treatment of depressive disorders
US20110245307A1 (en) Methods for Alzheimer's Disease Treatment and Cognitive Enhancement
WO2008143880A2 (fr) Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales
JP2017095468A (ja) 虚血／卒中誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
US20130331427A1 (en) Methods of stimulating cellular growth, synaptic, remodeling and consolidation of long-term memory

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2